Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 9/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | APAF1 | O14727 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22572291 | 0.77 | CYP1A2 (0.39) | NAAACYSLTR2CYSLTR1CYP1A2 | |
| SCHEMBL17027841 | 0.76 | LTB4R (0.68) | LTB4R | |
| SCHEMBL6344592 | 0.76 | LTB4R (0.68) | LTB4R | |
| SCHEMBL17027837 | 0.76 | LTB4R (0.68) | LTB4R | |
| SCHEMBL6971015 | 0.76 | LTB4R (0.68) | LTB4R | |
| SCHEMBL27514701 | 0.75 | LTB4R (0.53) | TBXAS1LTB4RACE2LTA4HNAAA | |
| SCHEMBL5977939 | 0.75 | ACE2 (0.64) | TBXAS1ACE2LTA4HBLMGABRR1 | |
| SCHEMBL20612872 | 0.75 | ACE2 (0.64) | TBXAS1ACE2LTA4HBLMGABRR1 | |
| SCHEMBL31073666 | 0.75 | ACE2 (0.64) | TBXAS1ACE2LTA4HBLMGABRR1 | |
| SCHEMBL9001608 | 0.75 | ACE2 (0.64) | TBXAS1ACE2LTA4HBLMGABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513233-B2 | Pyrimidinyl-propionic acid derivatives and their use as PPAR agonists | SHANGHAI INSTITUTE OF MATERIA MEDICA, CAS (CN) | 2013-08-20 | — | — | US | disclosed |
| US-20100240636-A1 | PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | SHENYANG SUNSHINE PHARMACEUTICAL COMPANY LIMITED (CN) | 2010-09-23 | — | — | US | disclosed |
| WO-2009046606-A1 | PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | SHANGHAI INSTITUTE OF MATERIA MEDICA, CAS (CN) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240636-A1 | PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | PPARA, PPARD, PPARG | TBXAS1 1065/4885LTB4R 2307/4885ACE2 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.